Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired disease that leads to the destruction of red blood cells, blood clots, and an impaired bone marrow caused due to the mutation in the PIGA (Phosphatidylinositol glycan class A) gene.
DelveInsight's brings another addition to its Newsletter Series focusing on a life-threatening disease of the blood.
The newsletter provides a brief introduction of the indication - Paroxysmal Nocturnal Hemoglobinuria, its epidemiological analysis, preponderance in different populations, treatment approaches, unmet needs in the market, and upcoming therapies in the future.
The newsletter presents the analysis of the present Paroxysmal Nocturnal Hemoglobinuria market scenario, key pharma companies working to drive the PNH market in the coming decade, key collaborations, and partnerships that are driving the market. Moreover, the newsletter proffers an overview of the top conferences scheduled for the following year as well as the support from international organizations to the PNH patients.
Read more about the PHN market by filling up the form to the right and get the newsletter directly delivered into your inbox.
Subscribe to our series for more such deep and rich insights into the pharma market.
Stay in the loop.
Know more about What's covered:
- Indication overview
- Epidemiological trends
- Treatment approaches
- Key Companies
- Pipeline drugs
- Recent happening in the PNH domain
- Top conferences
- R&D in the field
- Support from International organizations
